Figure 7: Noninvasive monitoring of nanophore drug releasein vivowith MRI.
From: Environment-responsive nanophores for therapy and treatment monitoring via molecular MRI quenching
Mice were injected with unloaded (FH) or Doxorubicin-loaded Ferumoxytol (Doxo-FH), and the tumours (a) T2 and (b) T2* signals were monitored across time (scale bars, 25 mm). (c) As Ferumoxytol released doxorubicin in vivo, the nanoparticles’ T2 signal gradually decreased and eventually reached that of the unloaded nanoparticles (mean±s.e.m.; n=3 per treatment group per time point). (d) The T2* indicated that the unloaded and loaded nanoparticles were equally retained at the tumours, as there were no differences in the T2* signal (mean±s.e.m.; n=3 per treatment group per time point).
